### üÜï NEW TESTS TO ADD
- **Labcorp Plasma Focus‚Ñ¢**: Liquid biopsy test using ctDNA to guide precision immunotherapy for lung cancer in the CRI BR.36 Phase 2/3 trial, measuring response after pembrolizumab cycles.[2] https://www.cancerresearch.org/media-room/labcorp-cri-br36
- **Caris Assure¬Æ**: Blood-based liquid biopsy platform powered by Assure Blood-based Cancer Detection AI (ABCDai), trained on over 376,000 tissue profiles; validates multi-cancer early detection (MCED) with 83.1‚Äì95.7% sensitivity across stages I‚ÄìIV at 99.6% specificity, plus therapy selection.[5] https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-announces-new-study-demonstrating-the-power-and-clinical-utility-of-caris-assure/
- **Cancerguard** (Exact Sciences): Multi-cancer early detection (MCED) test, commercially available in 2025.[3] https://www.aamc.org/news/liquid-biopsies-spark-hope-early-cancer-detection

### üì∞ REGULATORY/COMMERCIAL UPDATES  
- **Guardant360¬Æ CDx** (Guardant Health): Launched in-house liquid biopsy testing service at Policlinico Gemelli hospital in Italy (FPG 360), based on Guardant360 CDx technology certified under EU IVDR 2017/746 for solid tumor mutation profiling and companion diagnostics in NSCLC and breast cancer; expands access for routine care and clinical research.[4] https://www.businesswire.com/news/home/20251209949327/en/Guardant-Health-and-Policlinico-Gemelli-Launch-In-House-Liquid-Biopsy-Testing-Service-in-Italy

### üìö NEW PUBLICATIONS
- **Caris Assure¬Æ study** (Caris Life Sciences): New study demonstrates clinical utility in therapy selection, MCED (83.1‚Äì95.7% sensitivity stages I‚ÄìIV at 99.6% specificity), and performance across matched blood/tissue samples.[5] https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-announces-new-study-demonstrating-the-power-and-clinical-utility-of-caris-assure/

### ‚ö†Ô∏è DISCONTINUED/CHANGED
No discontinued tests or company acquisitions affecting availability identified among priority vendors in the search results.